David Ambinder, MD

David Ambinder, MD, is a urology resident at New York Medical College/Westchester Medical Center. His interests include surgical education, GU oncology, and advancements in technology in urology. A significant portion of his research has been focused on litigation in urology.

Articles by David Ambinder, MD

Dustin SamplesASCO GU Symposium 2023 | February 1, 2023
Get recommendations for sightseeing, dining, entertainment, and more while you're in town for the conference.
Read More
David Ambinder, MDRenal Cell Carcinoma | January 18, 2023
Cytoreductive nephrectomy is controversial in the metastatic RCC setting, especially in the age of immunotherapy.
David Ambinder, MDLocalized Prostate Cancer | January 18, 2023
With a lack of trials that address different surgical options for localized PC, is there evidence to guide patients?
David Ambinder, MDProstate Cancer | January 18, 2023
A recent review provides evidence of room for improvement in racial, ethnic group representation in clinical trials.
David Ambinder, MDJournal | December 19, 2022
Upfront cytoreductive nephrectomy for patients with MRCC with immune checkpoint inhibitors or targeted therapy is examined.
David Ambinder, MDJournal | December 19, 2022
According to a recent study published in The Lancet Oncology, radiation may offer safety and long-term efficacy for RCC.
David Ambinder, MDJournal | December 19, 2022
By administering immediate single-dose intravesical chemotherapy, there is a 15% absolute risk reduction in tumor recurrence.
David Ambinder, MDJournal | November 22, 2022
The multicenter phase 3 randomized controlled PHOTO trial examined if blue light cystoscopy could improve patient outcomes.
David Ambinder, MDJournal | November 22, 2022
Robert Uzzo gives an overview of the RENAL score that he developed, plus his outlook on the future of renal characterization.
David Ambinder, MDJournal | November 22, 2022
A study analyzing the safety and efficacy of large surface area microparticle docetaxel for NMIBC is reviewed.